Sonoma Pharmaceuticals (SNOA) Change in Receivables (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Change in Receivables of $168000.0 for Q1 2026, up 178.14% year-over-year from $60401.3 in Q1 2025, and up 149.41% quarter-over-quarter from -$340000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Change in Receivables (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Change in Receivables history runs 17 years deep, the most recent figure standing at $168000.0 for Q1 2026.
- In Q1 2026, Change in Receivables rose 178.14% year-over-year to $168000.0; the TTM figure through Mar 2026 stood at $122000.0 (up 128.11% YoY), while the FY2026 annual figure was $122000.0, up 128.11% from the prior year.
- Change in Receivables for Q1 2026 stood at $168000.0, up from -$340000.0 in the prior quarter.
- The five-year high for Change in Receivables was $596000.0 in Q4 2023, with the low at -$2.0 million in Q1 2022.
- The 5-year median for Change in Receivables is $9000.0 (2024), against an average of -$123941.2.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables soared 346.07% in 2024, then plunged 2488.89% in 2025.
- Sonoma Pharmaceuticals' Change in Receivables stood at -$289000.0 in 2022, then surged by 306.23% to $596000.0 in 2023, then sank by 208.39% to -$646000.0 in 2024, then jumped by 47.37% to -$340000.0 in 2025, then jumped by 149.41% to $168000.0 in 2026.
- Business Quant data shows SNOA's Change in Receivables at $168000.0 in Q1 2026, -$340000.0 in Q4 2025, and $78000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | 650,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 650,000.00 |
| Jun 30, 2026 | 650,000.00 |
| Mar 31, 2026 | 168,000.00 |
| Mar 31, 2026 | 168,000.00 |
| Dec 31, 2025 | -340,000.00 |
| Dec 31, 2025 | -340,000.00 |
| Sep 30, 2025 | 78,000.00 |
| Sep 30, 2025 | 78,000.00 |
| Jun 30, 2025 | 216,000.00 |
| Jun 30, 2025 | 216,000.00 |
| Mar 31, 2025 | -215,000.00 |
| Mar 31, 2025 | -215,000.00 |
| Dec 31, 2024 | -646,000.00 |
| Dec 31, 2024 | -646,000.00 |
| Sep 30, 2024 | -43,000.00 |
| Sep 30, 2024 | -43,000.00 |
| Jun 30, 2024 | 470,000.00 |
| Jun 30, 2024 | 470,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |